Lupin Limited has informed the Exchange regarding 'Inspection of U.S. FDA at the Company's Pithampur Unit-2 manufacturing facility'.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The U.S. FDA inspected Lupin's Pithampur Unit-2 manufacturing facility from July 8 to July 17, 2025. The inspection concluded with the issuance of a Form-483 carrying four observations. The company has stated it is addressing the observations comprehensively and will respond to the FDA within the required timeframe. Lupin reaffirmed its commitment to maintaining CGMP (current good manufacturing practice) quality standards across all facilities. The disclosure was made under SEBI's Regulation 30 listing requirements.
A Form-483 with a small number of observations (four) is relatively routine for pharma companies exporting to the U.S., but unresolved observations could escalate into a warning letter or import alert, which would affect U.S. shipments. Investors should monitor whether the company receives an Establishment Inspection Report (EIR) or further regulatory action from the FDA.